Effect of brimonidine on visual indices in patients with acute optic neuritis: A single blind randomized clinical trial

IF 2.9 3区医学 Q2 CLINICAL NEUROLOGY

Multiple sclerosis and related disorders Pub Date : 2024-09-30 DOI:10.1016/j.msard.2024.105913

Mohammed Arish , Meisam Sargazi , Mohammad Sedigh Dakkali , Sepide Mohammadzamani , Saeid Rasouli , Mahdi Asani

{"title":"Effect of brimonidine on visual indices in patients with acute optic neuritis: A single blind randomized clinical trial","authors":"Mohammed Arish , Meisam Sargazi , Mohammad Sedigh Dakkali , Sepide Mohammadzamani , Saeid Rasouli , Mahdi Asani","doi":"10.1016/j.msard.2024.105913","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>This study investigates brimonidine's potential effect on visual functions, particularly contrast sensitivity (CS), an indicator of retinal ganglion cell function.</div></div><div><h3>Methods</h3><div>In this single-blind, randomized clinical trial, 60 patients (aged 23–56) with first-episode acute optic neuritis within seven days of symptom onset were randomly assigned to brimonidine or control groups. The intervention group received brimonidine three times daily for three months, while the control group received synthetic tears with the same dosage and frequency. Primary outcomes were changes in CS, visual acuity (VA), and color vision at one and three months post-treatment. Repeated measures ANOVA was used to assess statistically significant and partial eta squared (η2) values, mean differences, and clinically significance important were reported.</div></div><div><h3>Results</h3><div>All participants completed the study without complications. VA improved significantly in both groups by follow-up end (<em>p</em> < 0.001), with significant improvement from first to third month only in the brimonidine group (<em>p</em> < 0.001). The mean VA difference between groups was not statistically and clinically significant. CS showed statistically significant improvement within both groups (<em>p</em> < 0.001) and between groups (<em>p</em> < 0.001), with a large effect size (partial η2 = 0.28). The mean CS difference between groups (14.5) was clinically considerable. No significant changes in color vision were observed between groups (<em>p</em> = 0.96).</div></div><div><h3>Conclusion</h3><div>Brimonidine significantly improved contrast sensitivity compared to placebo and was well-tolerated. Its neuroprotective effects suggest it may be beneficial in treating optic neuritis and preserving retinal ganglion cell function.</div></div><div><h3>Trial registration</h3><div>Prospectively registered at Iranian Clinical Trial Registration; Registration date 3 December 2022; Registration number: IRCT20221127056631N1</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"91 ","pages":"Article 105913"},"PeriodicalIF":2.9000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis and related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211034824004899","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This study investigates brimonidine's potential effect on visual functions, particularly contrast sensitivity (CS), an indicator of retinal ganglion cell function.

Methods

In this single-blind, randomized clinical trial, 60 patients (aged 23–56) with first-episode acute optic neuritis within seven days of symptom onset were randomly assigned to brimonidine or control groups. The intervention group received brimonidine three times daily for three months, while the control group received synthetic tears with the same dosage and frequency. Primary outcomes were changes in CS, visual acuity (VA), and color vision at one and three months post-treatment. Repeated measures ANOVA was used to assess statistically significant and partial eta squared (η2) values, mean differences, and clinically significance important were reported.

Results

All participants completed the study without complications. VA improved significantly in both groups by follow-up end (p < 0.001), with significant improvement from first to third month only in the brimonidine group (p < 0.001). The mean VA difference between groups was not statistically and clinically significant. CS showed statistically significant improvement within both groups (p < 0.001) and between groups (p < 0.001), with a large effect size (partial η2 = 0.28). The mean CS difference between groups (14.5) was clinically considerable. No significant changes in color vision were observed between groups (p = 0.96).

Conclusion

Brimonidine significantly improved contrast sensitivity compared to placebo and was well-tolerated. Its neuroprotective effects suggest it may be beneficial in treating optic neuritis and preserving retinal ganglion cell function.

Trial registration

Prospectively registered at Iranian Clinical Trial Registration; Registration date 3 December 2022; Registration number: IRCT20221127056631N1

查看原文本刊更多论文

溴莫尼定对急性视神经炎患者视觉指数的影响：单盲随机临床试验

目的：本研究探讨了溴莫尼定对视觉功能的潜在影响，尤其是对比敏感度（CS），它是视网膜神经节细胞功能的一个指标：在这项单盲随机临床试验中，60名首次发病的急性视神经炎患者（23-56岁）在症状出现后7天内被随机分配到溴莫尼定组或对照组。干预组接受溴莫尼定治疗，每日三次，为期三个月；对照组接受相同剂量和次数的合成泪液治疗。主要结果是治疗后一个月和三个月时CS、视力（VA）和色觉的变化。采用重复测量方差分析评估统计学意义，并报告了部分等方（η2）值、平均差异和重要临床意义：所有参与者都完成了研究，没有出现并发症。随访结束时，两组患者的视力均有明显改善（p < 0.001），只有溴莫尼定组在第一个月至第三个月有明显改善（p < 0.001）。各组之间的平均视力差异在统计学和临床上均无显着意义。CS在两组内（p < 0.001）和组间（p < 0.001）均有统计学意义上的明显改善，效应大小较大（部分η2 = 0.28）。各组之间的平均 CS 差值（14.5）在临床上相当大。组间色觉无明显变化（p = 0.96）：结论：与安慰剂相比，溴莫尼定能明显改善对比敏感度，且耐受性良好。结论：与安慰剂相比，溴莫尼定可明显改善对比敏感度，且耐受性良好。其神经保护作用表明，溴莫尼定可用于治疗视神经炎和保护视网膜神经节细胞功能：在伊朗临床试验注册中心进行了前瞻性注册；注册日期为 2022 年 12 月 3 日；注册号：IRCT20221127056631N1。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Multiple sclerosis and related disorders CLINICAL NEUROLOGY-

CiteScore

5.80

自引率

20.00%

发文量

814

审稿时长

66 days

期刊介绍： Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource. A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.